Publications scientifiques SARS-CoV-2 / Covid-19

La liste des publications scientifiques de l’Institut Pasteur relatives au coronavirus SARS-CoV-2 et à la maladie Covid-19. Mise à jour 18/02/2021




  1. Adam, D. C. et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nat Med (2020), doi:10.1038/s41591-020-1092-0, PMID:32943787I
  2. Ali, S. T. et al. Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions. Science 369, 1106-1109 (2020), doi:10.1126/science.abc9004, PMID:32694200I
  3. Alm, E. et al. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Euro Surveill 25 (2020), doi:10.2807/1560-7917.Es.2020.25.32.2001410, PMID:32794443I
  4. Anna, F. et al. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. Eur J Immunol (2020), doi:10.1002/eji.202049058, PMID:33259646I
  5. Baay, M. et al. SARS-CoV-2: Virology, epidemiology, immunology and vaccine development. Biologicals 66, 35-40 (2020), doi:10.1016/j.biologicals.2020.06.005, PMID:32600951I
  6. Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370 (2020), doi:10.1126/science.abd4585, PMID:32972996
  7. Batéjat, C., Grassin, Q., Manuguerra, J. C. & Leclercq, I. Heat inactivation of the severe acute respiratory syndrome coronavirus 2. J Biosaf Biosecur 3, 1-3 (2021), doi:10.1016/j.jobb.2020.12.001, PMID:33521591I
  8. Bauer, D. C. et al. Interoperable medical data: the missing link for understanding COVID-19. Transbound Emerg Dis (2020), doi:10.1111/tbed.13892, PMID:33095970
  9. Benetos, A. et al. The Nexus between Telomere Length and Lymphocyte Count in Seniors hospitalized with Covid-19. J Gerontol A Biol Sci Med Sci (2021), doi:10.1093/gerona/glab026, PMID:33528568I
  10. Bernard Stoecklin, S. et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill 25 (2020), doi:10.2807/1560-7917.Es.2020.25.6.2000094, PMID:32070465I
  11. Berteloot, L. et al. Arterial abnormalities identified in kidneys transplanted into children during the COVID-19 pandemic. Am J Transplant (2020), doi:10.1111/ajt.16464, PMID:33346946I
  12. Bielicki, J. A. et al. Monitoring approaches for health-care workers during the COVID-19 pandemic. Lancet Infect Dis 20, e261-e267 (2020), doi:10.1016/s1473-3099(20)30458-8, PMID:32711692I
  13. Boëlle, P. Y. et al. Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020. Euro Surveill 25 (2020), doi:10.2807/1560-7917.Es.2020.25.14.2000326, PMID:32290901I
  14. Bonam, S. R., Kaveri, S. V., Sakuntabhai, A., Gilardin, L. & Bayry, J. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. Cell Rep Med 1, 100016 (2020), doi:10.1016/j.xcrm.2020.100016, PMID:32562483I
  15. Bosetti, P. et al. Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France. Euro Surveill 26 (2021), doi:10.2807/1560-7917.Es.2020.26.1.2001978, PMID:33413741I
  16. Bost, P. et al. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell (2020), doi:10.1016/j.cell.2020.05.006, PMID:32479746I
  17. Bouhaddou, M. et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182, 685-712.e619 (2020), doi:10.1016/j.cell.2020.06.034, PMID:32645325I
  18. Bréchot, C. [The pandemic caused by SARS-CoV-2: more than a serious health crisis, a change of time and lessons to be learned urgently]. Med Sci (Paris) (2020), doi:10.1051/medsci/2020245, PMID:33200980I
  19. Buchrieser, J. et al. Syncytia formation by SARS-CoV-2 infected cells. Embo j, e106267 (2020), doi:10.15252/embj.2020106267, PMID:33051876I
  20. Cappy, P. et al. No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation. Blood 136, 1888-1891 (2020), doi:10.1182/blood.2020008230, PMID:32871595I
  21. Cauchemez, S., Kiem, C. T., Paireau, J., Rolland, P. & Fontanet, A. Lockdown impact on COVID-19 epidemics in regions across metropolitan France. Lancet (2020), doi:10.1016/s0140-6736(20)32034-1, PMID:33007219I
  22. Changeux, J. P., Amoura, Z., Rey, F. A. & Miyara, M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. C R Biol 343, 33-39 (2020), doi:10.5802/crbiol.8, PMID:32720486I
  23. Cocozza, F. et al. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus. J Extracell Vesicles 10, e12050 (2020), doi:10.1002/jev2.12050, PMID:33391636I
  24. Coutard, B., Romette, J. L., Miyauchi, K., Charrel, R. & Prat, C. M. A. The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 Crisis. Biopreserv Biobank (2020), doi:10.1089/bio.2020.0119, PMID:33181021I
  25. Crawford, K. H. D. et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses 12 (2020), doi:10.3390/v12050513, PMID:32384820I
  26. Cocozza, F. et al. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus. J Extracell Vesicles 10, e12050 (2020), doi:10.1002/jev2.12050, PMID:33391636I
  27. Coutard, B., Romette, J. L., Miyauchi, K., Charrel, R. & Prat, C. M. A. The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 Crisis. Biopreserv Biobank (2020), doi:10.1089/bio.2020.0119, PMID:33181021I
  28. Denis, F. et al. Epidemiological Observations on the Association Between Anosmia and COVID-19 Infection: Analysis of Data From a Self-Assessment Web Application. J Med Internet Res 22, e19855 (2020), doi:10.2196/19855, PMID:32496206I
  29. Du, Z. et al. Risk for Transportation of Coronavirus Disease from Wuhan to Other Cities in China. Emerg Infect Dis 26, 1049-1052 (2020), doi:10.3201/eid2605.200146, PMID:32053479I
  30. Du, Z. et al. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerg Infect Dis 26, 1341-1343 (2020), doi:10.3201/eid2606.200357, PMID:32191173I
  31. Fafi-Kremer, S. et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine, 102915 (2020), doi:10.1016/j.ebiom.2020.102915, PMID:32747185I
  32. Fertitta, L. et al. Immunological and virological profile of children with chilblain-like lesions and SARS-CoV-2. J Eur Acad Dermatol Venereol (2020), doi:10.1111/jdv.16972, PMID:33010072I
  33. Finlay, B. B. et al. The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome. Proc Natl Acad Sci U S A 118 (2021), doi:10.1073/pnas.2010217118, PMID:33472859I
  34. Fontanet, A. et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet (2021), doi:10.1016/s0140-6736(21)00370-6, PMID:33581803I
  35. Fontanet, A. & Cauchemez, S. COVID-19 herd immunity: where are we? Nat Rev Immunol (2020), doi:10.1038/s41577-020-00451-5, PMID:32908300I
  36. Fritz, M. et al. High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households. One Health 11, 100192 (2021), doi:10.1016/j.onehlt.2020.100192, PMID:33169106I
  37. Galmiche, S. et al. Implementing a self-triage web-application for suspected COVID-19 patients' triage: impact on emergency call centers. J Med Internet Res (2020), doi:10.2196/22924, PMID:33147165I
  38. Gámbaro, F. et al. Introductions and early spread of SARS-CoV-2 in France, 24 January to 23 March 2020. Euro Surveill 25 (2020), doi:10.2807/1560-7917.Es.2020.25.26.2001200, PMID:32643599I
  39. Garfinkel, M., Sansonetti, P. J. & Pulverer, B. Survival of the Wealthiest? Embo j, e107227 (2020), doi:10.15252/embj.2020107227, PMID:33205839I
  40. Garigliany, M. et al. SARS-CoV-2 Natural Transmission from Human to Cat, Belgium, March 2020. Emerg Infect Dis 26 (2020), doi:10.3201/eid2612.202223, PMID:32788033I
  41. Garneret, P. et al. Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification. PLoS One 16, e0243712 (2021), doi:10.1371/journal.pone.0243712, PMID:33428641I
  42. Gordon, D. E. et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science (2020), doi:10.1126/science.abe9403, PMID:33060197I
  43. Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459-468 (2020), doi:10.1038/s41586-020-2286-9, PMID:32353859I
  44. Goyard, S. et al. A highly sensitive bioluminescent method for measuring allergen-specific IgE in microliter samples. Allergy (2020), doi:10.1111/all.14365, PMID:32407549I
  45. Grzelak, L. et al. Sex differences in the decline of neutralizing antibodies to SARS-CoV-2. medRxiv, 2020.2011.2012.20230466 (2020), doi:10.1101/2020.11.12.20230466
  46. Guillier, L. et al. Modelling the inactivation of viruses from the Coronaviridae family in response to temperature and relative humidity in suspensions or surfaces. Appl Environ Microbiol (2020), doi:10.1128/aem.01244-20, PMID:32680860I
  47. Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718-724 (2020), doi:10.1126/science.abc6027, PMID:32661059I
  48. Heyerdahl, L. W. et al. Evaluating the motivation of Red Cross Health volunteers in the COVID-19 pandemic: a mixed-methods study protocol. BMJ Open 11, e042579 (2021), doi:10.1136/bmjopen-2020-042579, PMID:33500285I
  49. Hourdel, V. et al. Rapid Genomic Characterization of SARS-CoV-2 by Direct Amplicon-Based Sequencing Through Comparison of MinION and Illumina iSeq100(TM) System. Front Microbiol 11, 571328 (2020), doi:10.3389/fmicb.2020.571328, PMID:33101244I
  50. Huang, A. T. et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun 11, 4704 (2020), doi:10.1038/s41467-020-18450-4, PMID:32943637I
  51. Johansen, M. D. et al. Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunol 13, 877-891 (2020), doi:10.1038/s41385-020-00340-z, PMID:32820248I
  52. Kervevan, J. & Chakrabarti, L. A. Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions. Int J Mol Sci 22 (2021), doi:10.3390/ijms22020523, PMID:33430234I
  53. Kim, D. K. et al. A Comprehensive, Flexible Collection of SARS-CoV-2 Coding Regions. G3 (Bethesda) (2020), doi:10.1534/g3.120.401554, PMID:32763951I
  54. Kraemer, M. U. G. et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. Science 368, 493-497 (2020), doi:10.1126/science.abb4218, PMID:32213647I
  55. Ku, M. W. et al. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe 29, 236-249.e236 (2021), doi:10.1016/j.chom.2020.12.010, PMID:33357418I
  56. Labadie, T., Batéjat, C., Leclercq, I. & Manuguerra, J. C. Historical Discoveries on Viruses in the Environment and Their Impact on Public Health. Intervirology, 1-16 (2020), doi:10.1159/000511575, PMID:33238280I
  57. Lecuit, M. Chloroquine and COVID-19, where do we stand? Med Mal Infect 50, 229-230 (2020), doi:10.1016/j.medmal.2020.03.004, PMID:32217166I
  58. Lemoine, F., Blassel, L., Voznica, J. & Gascuel, O. COVID-Align: Accurate online alignment of hCoV-19 genomes using a profile HMM. Bioinformatics (2020), doi:10.1093/bioinformatics/btaa871, PMID:33045068I
  59. Lemoine, M. et al. Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa. Lancet Gastroenterol Hepatol 5, 966-967 (2020), doi:10.1016/s2468-1253(20)30305-8, PMID:32950107I
  60. Lescure, F. X. et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 20, 697-706 (2020), doi:10.1016/s1473-3099(20)30200-0, PMID:32224310I
  61. Lunz, D., Batt, G. & Ruess, J. To quarantine, or not to quarantine: A theoretical framework for disease control via contact tracing. Epidemics 34, 100428 (2020), doi:10.1016/j.epidem.2020.100428, PMID:33444928I
  62. Maisonnasse, P. et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature 585, 584-587 (2020), doi:10.1038/s41586-020-2558-4, PMID:32698191I
  63. Marot, S. et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun 12, 844 (2021), doi:10.1038/s41467-021-21111-9, PMID:33558507I
  64. Mavian, C. et al. Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable. Proc Natl Acad Sci U S A 117, 12522-12523 (2020), doi:10.1073/pnas.2007295117, PMID:32381734I
  65. Michel, C. J., Mayer, C., Poch, O. & Thompson, J. D. Characterization of accessory genes in coronavirus genomes. Virol J 17, 131 (2020), doi:10.1186/s12985-020-01402-1, PMID:32854725I
  66. Mögling, R. et al. Delayed Laboratory Response to COVID-19 Caused by Molecular Diagnostic Contamination. Emerg Infect Dis 26, 1944-1946 (2020), doi:10.3201/eid2608.201843, PMID:32433015I
  67. O'Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature (2020), doi:10.1038/s41586-020-2918-0, PMID:33137809I
  68. Ostaszewski, M. et al. COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. Sci Data 7, 136 (2020), doi:10.1038/s41597-020-0477-8, PMID:32371892I
  69. Piccoli, L. et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 183, 1024-1042.e1021 (2020), doi:10.1016/j.cell.2020.09.037, PMID:32991844I
  70. Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature (2020), doi:10.1038/s41586-020-2349-y, PMID:32422645I
  71. Plaze, M. et al. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. Encephale 46, 169-172 (2020), doi:10.1016/j.encep.2020.05.006, PMID:32425222I
  72. Plaze, M. et al. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. Int J Antimicrob Agents, 106274 (2020), doi:10.1016/j.ijantimicag.2020.106274, PMID:33387629I
  73. Roederer, T. et al. Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study. Lancet Public Health (2021), doi:10.1016/s2468-2667(21)00001-3, PMID:33556328I
  74. Rosado, J. et al. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe 2, e60-e69 (2021), doi:10.1016/s2666-5247(20)30197-x, PMID:33521709I
  75. Sa Ribero, M., Jouvenet, N., Dreux, M. & Nisole, S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog 16, e1008737 (2020), doi:10.1371/journal.ppat.1008737, PMID:32726355I
  76. Sailleau, C. et al. First detection and genome sequencing of SARS-CoV-2 in an infected cat in France. Transbound Emerg Dis (2020), doi:10.1111/tbed.13659, PMID:32500944I
  77. Salje, H. et al. Estimating the burden of SARS-CoV-2 in France. Science 369, 208-211 (2020), doi:10.1126/science.abc3517, PMID:32404476I
  78. Sansonetti, P. J. COVID-19, chronicle of an expected pandemic. EMBO Mol Med 12, e12463 (2020), doi:10.15252/emmm.202012463, PMID:32259394I
  79. Sarkar, M. & Saha, S. Structural insight into the role of novel SARS-CoV-2 E protein: A potential target for vaccine development and other therapeutic strategies. PLoS One 15, e0237300 (2020), doi:10.1371/journal.pone.0237300, PMID:32785274I
  80. Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science (2020), doi:10.1126/science.abe3255, PMID:33154106I
  81. Silvin, A. et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell 182, 1401-1418.e1418 (2020), doi:10.1016/j.cell.2020.08.002, PMID:32810439I
  82. Smadja, D. M. et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis 23, 611-620 (2020), doi:10.1007/s10456-020-09730-0, PMID:32458111I
  83. Smith, D. R. M. et al. Optimizing COVID-19 surveillance in long-term care facilities: a modelling study. BMC Med 18, 386 (2020), doi:10.1186/s12916-020-01866-6, PMID:33287821I
  84. Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell (2021), doi:10.1016/j.cell.2021.01.050, PMID:33571429I
  85. Spiteri, G. et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill 25 (2020), doi:10.2807/1560-7917.Es.2020.25.9.2000178, PMID:32156327I
  86. Sterlin, D. & Gorochov, G. When Therapeutic IgA Antibodies Might Come of Age. Pharmacology, 1-11 (2020), doi:10.1159/000510251, PMID:32950975I
  87. Tekpinar, M. & Yildirim, A. Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases. J Biomol Struct Dyn, 1-12 (2021), doi:10.1080/07391102.2021.1880481, PMID:33525993I
  88. Temime, L. et al. A Conceptual Discussion about R0 of SARS-COV-2 in Healthcare Settings. Clin Infect Dis (2020), doi:10.1093/cid/ciaa682, PMID:32473007I
  89. Temmam, S. et al. Absence of SARS-CoV-2 infection in cats and dogs in close contact with a cluster of COVID-19 patients in a veterinary campus. One Health, 100164 (2020), doi:10.1016/j.onehlt.2020.100164, PMID:32904469I
  90. Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science (2020), doi:10.1126/science.abe3354, PMID:32972994I
  91. Tubiana, S. et al. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in in-hospital workers - the CoV-CONTACT cohort. J Infect (2021), doi:10.1016/j.jinf.2021.01.026, PMID:33545165I
  92. van der Werf, S. & Peltekian, C. Facing challenges with the novel coronavirus SARS-CoV-2 outbreak. Virologie (Montrouge) 24, e12-15 (2020), doi:10.1684/vir.2020.0826, PMID:32186279I
  93. Veyer, D. et al. Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. Clin Infect Dis (2020), doi:10.1093/cid/ciaa1196, PMID:32803231I
  94. Vieira, M. et al. Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. Joint Bone Spine. 2020;87:191-93. Joint Bone Spine (2020), doi:10.1016/j.jbspin.2020.09.006, PMID:32950702I
  95. Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292 e286 (2020), doi:10.1016/j.cell.2020.02.058, PMID:32155444I
  96. White, K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science (2021), doi:10.1126/science.abf4058, PMID:33495306I
  97. Xu, B. et al. Epidemiological data from the COVID-19 outbreak, real-time case information. Sci Data 7, 106 (2020), doi:10.1038/s41597-020-0448-0, PMID:32210236I
  98. Xu, X. K. et al. Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. Clin Infect Dis (2020), doi:10.1093/cid/ciaa790, PMID:32556265I
  99. Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370 (2020), doi:10.1126/science.abd4570, PMID:32972995I
  100. Zhukova, A. et al. Origin, evolution and global spread of SARS-CoV-2. C R Biol (2020), doi:10.5802/crbiol.29, PMID:33274614I


Retour en haut